Most Read Articles
5 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Elvira Manzano, 06 Feb 2020
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Endoscopic resection with selective CRT effective for oesophageal squamous cell carcinoma

09 Aug 2019

The combination of endoscopic resection (ER) and selective chemoradiotherapy (CRT) is effective for stage T1b N0M0 thoracic oesophageal squamous cell carcinoma (ESCC), a recent study has found.

Researchers prospectively assessed 176 patients (median age, 63 years; 147 males) with T1b N0M0 thoracic ESCC who underwent ER. Based on resection findings, participants received one of three therapy regimens: no additional treatment (group A; n=74), prophylactic CRT at 41.4 Gy delivered to locoregional lymph nodes (group B; n=83) and definitive CRT at 50.4 Gy with a 9-Gy boost to the primary site (group C; n=13).

The 3-year overall survival rate in group B, the study’s primary outcome, was 90.7 percent (90 percent CI, 84.0–94.7). In the overall sample, the corresponding rate was 92.6 percent (88.5–95.2). This indicated that CRT was either comparable to or superior than surgical intervention, said researchers.

Fifteen patients developed metastatic recurrence of the malignancy, including one in group A, 10 in group B and four in group C. Seven patients with recurrent cancer in only the lymph nodes received salvage surgery; two were alive at the final follow-up. The 3-year progression-free survival rate for the overall sample was 89.7 percent.

There were 18 deaths over the entire study period, though none were related to the treatment regimen. Oesophageal cancer was responsible for 11 deaths, including one in group A, seven in group B and three in group C. Other (brain haemorrhage, acute pancreatitis and pneumonia, among others) and unknown causes accounted for the remaining mortalities.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Elvira Manzano, 06 Feb 2020
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.